{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

40 delegates to take part in MSIF's spring Board and Committee meetings

MSIF's annual spring Board and Committee meetings are taking place from 18-20 April in London, UK.

read more

Do you use our My World of MS online community?

If so, have your say on its future development by taking part in our new survey.

read more

MSIF Deputy Chief Executive chairs IAPO forum

Paul Rompani chaired the International Alliance of Patients’ Organizations' (IAPO) day-long forum on Friday 30 March to discuss international issues affecting patients' organisations.

read more

back to top

Profile of the Month : January 2008

Erlend Berntsen

Age: 27
Country: Norway
Occupation: Admissions Officer
Year of diagnosis: 2000

"I’ve tried to maintain my hopes and dreams for the future."

English Italiano Espanol Deutsch Francais Russian

read more

back to top

The effect of interferon-beta (1a) on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis.

This clinical trial evaluated the impact of interferon beta on the disease course in people with their first clinical episode suggestive of MS. They found it to be useful in delaying progression to disability and preventing some new relapses.

authors: Motamed MR, Najimi N, Fereshtehnejad SM.

source: Clin Neurol Neurosurg. 2007 May;109(4):344-9.

read more

Current perspectives on FTY720

The authors reviewed the most recent studies about oral fingolimod, a promising drug for many autoimmune diseases like MS, with an effective immunosuppressant action and relatively few side effects.

authors: Martini S, Peters H, Bohler T, Budde K.

source: Expert Opin Investig Drugs. 2007 Apr;16(4):505-18

read more

Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis

The authors evaluated the effectiveness of magnetically stimulating the brain area which controls movement in treating spasticity in people with MS, and found it to be useful.

authors: Centonze D, Koch G, Versace V, Mori F, Rossi S, Brusa L, Grossi K, Torelli F, Prosperetti C, Cervellino A, Marfia GA, Stanzione P, Marciani MG, Boffa L, Bernardi G.

source: Neurology. 2007 Mar 27;68(13):1045-50.

read more

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

The authors review the most relevant evidence about the clinical and radiological impact of antibodies against interferon beta in people with MS.

authors: Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.

source: Neurology. 2007 Mar 27;68(13):977-84.

read more

Reactivation of JC virus and development of PML in patients with multiple sclerosis

The authors review the role and the mechanism of action of JC virus in causing progressive multifocal leukoencephalopathy, a serious but rare adverse event that recently occurred in two patients with MS involved in a clinical trial with Natalizumab.

authors: Khalili K, White MK, Lublin F, Ferrante P, Berger JR.

source: Neurology. 2007 Mar 27;68(13):985-90.

read more

back to top

Record number of countries sign UN treaty on disabilities on opening day

source: United Nations

Eighty-one Member States and the European Community signed a landmark new treaty on 30 March 2007 at the United Nations that aims to improve the lives of the world’s estimated 650 million people with disabilities, a record for the first day of signature of any convention.

read more

UK MS Society appalled at Tysabri recommendation

source: UK MS Society

NICE, the UK Government's drug watchdog, has recommended against the prescription of one of the most effective drugs so far developed to treat MS, the UK MS Society says.

read more

Researchers stop MS-like disease in mice by targeting a blood protein

source: US National MS Society

A new study funded in part by the US National MS Society shows for the first time that blocking a segment of fibrinogen – a protein essential for blood clotting – reduces inflammation and symptoms in mice with an MS-like disease, apparently without interfering with normal blood clotting.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.